文献速递类风湿关节炎

IgA抗瓜氨酸化蛋白抗体与类风湿关节炎DMARD减量期间复发相关

IgA anti-citrullinated protein antibodies are associated with flares during DMARD tapering in rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

在108例来自随机对照RETRO研究的RA患者中,评估基线及12个月时IgA1和IgA2 ACPA水平与DMARD减量后复发的关系。稳定缓解患者中,未复发者IgA2 ACPA水平和IgA2% ACPA显著下降(中位数17.5%;P<0.0001),IgA2% ACPA与复发时DAS28相关(r=0.36;P=0.046)。IgA ACPA联合IgG ACPA被确定为复发风险因素。

要点

  • 稳定缓解的RA患者中,未复发者IgA2 ACPA水平及IgA2% ACPA显著下降。
  • IgA2% ACPA与复发时DAS28相关(r=0.36;P=0.046)。
  • IgA与IgG ACPA对复发风险有独立贡献趋势,双阳性风险最高。

核心结论

  • IgA ACPA联合IgG ACPA是RA患者DMARD减量期间复发的风险因素。
  • IgA2 ACPA水平与复发严重程度相关,并在稳定缓解患者中下降。

研究设计与样本

  • 来自随机对照RETRO研究的108例RA患者,基线及12个月时检测IgA1和IgA2 ACPA。
  • 研究招募时稳定缓解至少6个月的患者被分配至DMARD减量组或继续治疗组。

主要发现

  • 未复发患者中IgA2 ACPA水平和IgA2% ACPA显著下降(中位数17.5%;P<0.0001),复发患者中无此变化。
  • IgA2 ACPA动态在研究组间无差异,似乎独立于治疗选择。
  • IgA2% ACPA与复发时DAS28相关(r=0.36;P=0.046)。
  • IgA和IgG ACPA对复发风险有独立贡献趋势,双抗体阳性患者风险最高。

关键数值与推荐

  • IgA2% ACPA下降中位数为17.5%(P<0.0001)。
  • IgA2% ACPA与复发时DAS28的相关系数r=0.36(P=0.046)。

临床怎么用

  • 在RA患者DMARD减量决策中,可考虑检测IgA ACPA(尤其IgA2)以辅助评估复发风险。
  • IgA与IgG ACPA双阳性可能提示更高复发风险,需加强监测。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A substantial proportion of RA patients flare upon withdrawal of DMARDs, and thus the definition of prognostic markers is crucial. ACPA positivity has been identified as a risk factor for flare. However, only the role of IgG ACPA is established in this context, while the role of IgA ACPA is poorly defined. We thus aimed to investigate the role of IgA ACPA in flaring of RA. METHODS: Serum levels of IgA1 and IgA2 ACPA at baseline and after 12 months were measured in 108 patients from the randomized controlled RETRO study. RA patients in stable remission for at least 6 months at study recruitment were assigned to either one of the DMARD tapering arms or to continuation of DMARDs. RESULTS: In patients remaining in remission but not in the ones who flared, IgA2 ACPA levels and proportion of IgA2 in ACPA (IgA2% ACPA) significantly declined (median of 17.5%; P < 0.0001). This seemed to be independent of the treatment choice, as there was no difference in IgA2 ACPA dynamics between the study arms. IgA2% ACPA was associated with disease activity (DAS28) at flare (r = 0.36; P = 0.046). IgA and IgG ACPA showed a tendency towards independent contribution to the risk of flare with the highest risk if a patient had both antibody classes. CONCLUSION: In this study, IgA ACPA was identified as a risk factor for flare in combination with IgG ACPA. IgA2 ACPA levels were associated with flare severity and declined in patients in stable remission.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sokolova MV, Hagen M, Bang H, et al. IgA anti-citrullinated protein antibodies are associated with flares during DMARD tapering in rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34508547. doi:10.1093/rheumatology/keab585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。